Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
about
Hepatitis C: Treatment of difficult to treat patientsHCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeInvestigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment.Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals.
P2860
Q26798465-C2E3A418-9A2D-4A71-BAC1-51716F580CF2Q31012317-A5C22C63-5DFB-4345-93A4-F2FE2AA0A272Q31051529-2154DA66-EF79-40FB-B607-C8E92CCA895FQ33422417-45CF8FA0-05FC-4219-93D9-6C51F83361D2Q34589830-B3E69BBB-E5F7-404D-975D-2B7D66BD2F6AQ35773677-CFBBC8D9-43A5-4743-8C0C-BC55440531B2Q37625268-DD82BE5A-B10F-44AD-9E49-805CD1BF7339Q38341993-4CB4D229-23E9-41FD-841F-1D8B90FB5325Q39249225-20E7DA47-2FA7-448D-B7F3-E77F17CD6757Q39910149-E62EF347-D64C-4C18-BE5B-1D68BF85E179Q41469280-A312A088-0134-49C6-BCD7-7C2932CAE724Q41655360-4D7057BD-BD20-4187-9798-9F71F424B418Q41703167-41D0E677-E7EA-47E9-A6CE-B197CBF30A5FQ43100552-30D8DAB4-2BFD-406B-8224-14F0D84D6C12
P2860
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety and efficacy of bocepre ...... cs: meta-analysis of 5 trials.
@ast
Safety and efficacy of bocepre ...... cs: meta-analysis of 5 trials.
@en
type
label
Safety and efficacy of bocepre ...... cs: meta-analysis of 5 trials.
@ast
Safety and efficacy of bocepre ...... cs: meta-analysis of 5 trials.
@en
prefLabel
Safety and efficacy of bocepre ...... cs: meta-analysis of 5 trials.
@ast
Safety and efficacy of bocepre ...... cs: meta-analysis of 5 trials.
@en
P2093
P50
P1476
Safety and efficacy of bocepre ...... cs: meta-analysis of 5 trials.
@en
P2093
Bruce R Bacon
Frank J Dutko
Frans A Helmond
Janice Wahl
Jean-Pierre Bronowicki
John M Vierling
Kenneth J Koury
Lisa D Pedicone
Mark J DiNubile
Michael P Manns
P304
P356
10.1016/J.JHEP.2014.03.022
P577
2014-04-18T00:00:00Z